research Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines
Early intervention and tailored management can reduce skin side effects from cancer treatments.
Search
for
Sort by
Research
30-60 / 440 results
research Drug-Induced Acne: Causes, Diagnosis, and Treatment
Some medications can cause acne, and stopping these drugs is the main treatment.
research Tyrosine Kinase Inhibitors Against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Chemotherapy and Cutaneous Drug Reactions
Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.
research Gefitinib: An Adverse Effects Profile
Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
research Dermatological Adverse Effects of Chemotherapeutic Agents: Experience from a Tertiary Centre
About 22% of cancer patients had skin-related side effects from chemotherapy, but these were usually not severe enough to halt treatment.
research Index
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research The Management of EGFR Inhibitor Adverse Events: A Case Series and Treatment Paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research Cutaneous Toxicities of New Treatments for Melanoma
New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
research Cutaneous Adverse Reactions Linked to Targeted Anticancer Therapies Bortezomib and Lenalidomide for Multiple Myeloma: New Drugs, Old Side Effects
The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
research Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: The Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
research Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
research Cutaneous Reactions to Chemotherapeutic Drugs and Targeted Therapy for Cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research PRIDE Syndrome Associated With Panitumumab Treatment – Case Report and Literature Review
A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
research Mario Lacouture: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
research Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
research Management of Toxicities of Targeted Therapies
Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
research Dermatologic Adverse Events Associated With Afatinib: An Oral ErbB Family Blocker
Afatinib often causes skin problems that need proactive management.
research Dermatologic Adverse Events in Pediatric Patients Receiving Targeted Anticancer Therapies: A Pooled Analysis
Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.
research Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib
Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
research First-In-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
research Trichomegaly of the Eyelashes Following Treatment with Cetuximab
Cetuximab can cause excessive eyelash growth.
research Folliculitis Decalvans-Like Alopecia During EGFR Inhibitors Treatment for Lung Cancer: A Case Series of 6 Patients
Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.
research Perspectives in Head and Neck Medical Oncology
The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.